Novo Nordisk Zenagamtide, a pioneering investigational once-weekly subcutaneous treatment, has demonstrated statistically significant reductions in blood sugar alongside remarkable weight loss in adults with type 2 diabetes. Unveiled at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) in New Orleans, Louisiana, the Phase 2 clinical trial highlights the therapeutic potential of this first-of-its-class unimolecular peptide agonist. By targeting both GLP-1 and amylin receptors simultaneously, the drug marks a notable shift in metabolic care.
The 36-week, randomized, double-blind, placebo-controlled dose-finding study evaluated 262 adults with type 2 diabetes who were inadequately controlled on metformin, with or without an SGLT2 inhibitor. Participants were randomized across six subcutaneous doses ranging from 0.4 mg to 40 mg versus a matched placebo. The trial successfully met its primary endpoint of significant HbA1C reduction across all evaluated doses, showcasing strong efficacy even though higher dose cohorts were only exposed to their full maintenance doses for a short period.
Clinical Efficacy and Glycemic Impact of Novo Nordisk Zenagamtide
The trial data revealed a clear dose-dependent reduction in HbA1C from a baseline of 7.8%. At the highest evaluated dose of 40 mg, Novo Nordisk Zenagamtide achieved an estimated mean change in HbA1C of up to ‒1.71% at week 36 (estimated treatment difference vs placebo: ‒1.56% [95% CI: ‒2.05, ‒1.07]; p<0.0001). Furthermore, an impressive 89.1% of participants receiving the treatment achieved an HbA1C below 7%, while 76.2% reached a target of 6.5% or lower.
In addition to absolute blood sugar reductions, patients experienced optimized glucose stability throughout the day. The proportion of time spent within the recommended target range of 70–180 mg/dL (3.9–10.0 mmol/L) exceeded the international benchmark of >70% across all doses, peaking at 91.4% in the 40 mg cohort. This indicates a highly predictable and sustained glycemic control profile, reinforcing why clinicians prioritize comprehensive Type 2 Diabetes Management strategies.
Beyond glucose control, weight management served as a key supportive secondary endpoint. Participants treated with the highest dose of Novo Nordisk Zenagamtide experienced a mean body weight reduction of up to 14.6% from a baseline weight of approximately 219 lbs (99.2 kg), compared to just 2.1% in the placebo group. Crucially, investigators noted that no apparent weight loss plateau was observed by week 36 for the higher dosage tiers, suggesting that further weight loss could be achievable with extended treatment.
Safety Profile and Future Outlook for Novo Nordisk Zenagamtide
From a safety perspective, the tolerability of Novo Nordisk Zenagamtide aligned closely with established incretin and amylin-based therapies. The most frequently reported adverse events were gastrointestinal, with the vast majority categorized as mild to moderate in severity. Because the trial utilized a fixed-dose-escalation design, patients who could not tolerate their planned treatment dose permanently discontinued therapy, yet the overall safety profile strongly supports advancing the peptide into larger cohorts.
Zenagamtide is the first investigational treatment for type 2 diabetes to combine a GLP-1 and amylin receptor agonist mechanisms of action in a single molecule. These phase 2 results build on the growing body of evidence which demonstrates the potential of zenagamtide to meaningfully impact blood glucose control in patients with type 2 diabetes and also body weight in people living with obesity.
Martin Holst Lange, chief scientific officer and executive vice president, Research & Development at Novo Nordisk.
With these positive phase 2b results finalized, Novo Nordisk plans to initiate a comprehensive Phase 3 development program in the second half of 2026. This timeline is vital given the staggering public health burden; according to 2023 CDC data, over 40.1 million Americans live with diabetes, with type 2 diabetes accounting for 90% to 95% (36 to 38 million individuals) of those cases. For deeper industry insights on clinical developments, visit the official American Diabetes Association registry.
Trial Baseline Characteristics (N=262)
| Parameter | Value / Metric |
| Total Cohort (N) | 262 participants |
| Gender Distribution | 66% Male |
| Mean Age | 57.1 years |
| Baseline HbA1C | 7.8% |
| Baseline Body Weight | 99.2 kg (218.7 lbs) |
| Concomitant SGLT2i Use | 40% |
| Background Therapy | Stable dose of Metformin |
36-Week Efficacy Endpoints by Subcutaneous Dosage
| Treatment Group | Sample Size (n) | Mean HbA1C Change (%-points) | Mean Body Weight Change (%) | Max % of Patients with HbA1C < 7.0% | Max % of Patients with HbA1C ≤ 6.5% | Max Time in Target Range (70–180 mg/dL) |
| Zenagamtide 0.4 mg | 225 (pooled) | -0.91% | -4.35% | — | — | >70.0% |
| Zenagamtide 1.5 mg | 225 (pooled) | -1.31% | -7.62% | — | — | >70.0% |
| Zenagamtide 5.0 mg | 225 (pooled) | -1.00% | -8.19% | — | — | >70.0% |
| Zenagamtide 10.0 mg | 225 (pooled) | -1.41% | -12.92% | — | — | >70.0% |
| Zenagamtide 20.0 mg | 225 (pooled) | -1.64% | -13.13% | — | — | >70.0% |
| Zenagamtide 40.0 mg | 225 (pooled) | -1.71% | -14.60% | 89.1% | 76.2% | 91.4% |
| Pooled Placebo | 37 | -0.14% | -2.10% | — | — | — |
